Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats schizophrenia. Sold as Zyprexa Relprevv. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Olanzapine Pamoate (sold as Zyprexa Relprevv), first approved Dec 11, 2009, with 0 new uses approved and 0 published complete response letters.
First approved: Dec 11, 2009
Applications: 1
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $1.6M
Safety program: REMS
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Zyprexa Relprevv
Part D
$1.6M
+9%
154
Zyprexa Relprevv
Part B
$46K
-28%
160
Safety Programs (REMS)
FDA requires these when a drug's risks need more than a label: training, enrollment or extra checks before it is prescribed or dispensed
Program
Updated
Zyprexa Relprevv REMSRestricted: prescribers, pharmacies or patients must be certified or enrolled · Medication Guide for patients · Letters to doctors
Jul 6, 2026
Clinical Trials
58 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
